Renovation of the Possingergasse site completed

The Austrian drug approval agency AGES PharmMed states that both patients and physicians can assume that the benefit of a drug used in its field of application is in an acceptable ratio to the risk. The task of AGES PharmMed as the national drug…

BASG / AGES PharmMed states that the repeatedly cited AGES report is a document from March 2008. The results of the investigation documented in the report are now obsolete. The proceedings against Humanplasma, which were ongoing at that time, have…

In January 2009, AGES PharmMed conducted the second customer survey since its foundation in 2006. As in the previous survey, marketing authorization holders of proprietary medicinal products were addressed. In contrast to the first survey, the survey…

BASG/AGES PharmMed warn against the use of the weight loss tea "Paiyouji". Analyses in the Austrian Drug Control Laboratory (OMCL of AGES PharmMed) showed that this product contains a possibly carcinogenic indicator substance as well as a chemical…

In 2006, after the completion of the major review of pharmaceutical legislation, the Commission published ideas to further improve the legislation of proprietary medicinal product variation applications. The basic idea was: Simplification of…

Re-emergence of a case in Bucharest.

Occurrence of a confirmed case in the province of Bologna/Ferrara.

The following quality defect has been identified in the drug product Ionsys (Fentanyl) 40 microgram per dose iontophoretic transdermal system: A defect in the IONSYS systems may potentially cause the system to self-activate. See related files.

Exchange of unbuffered and weakly buffered infusion solutions. See associated files.